MetaCap

Jade Biosciences (JBIO) vs Omeros (OMER)

Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.

Summary

Omeros (OMER) has outperformed Jade Biosciences (JBIO) over the past year, gaining 48.9% versus a gain of 27.6%. Over five years, OMER leads with a +77.8% price change compared with -96.7% for JBIO. Jade Biosciences is the larger company by market cap ($1.06 billion vs $983.7 million), about 1.1 times the size.

Summary generated from market data by MetaCap's automated system. Methodology

Relative performance

JBIO+27.58%OMER+48.93%
+144%+67%-10%
Nov 21, 20251 yearNov 20, 2026
JBIO-96.93%OMER+67.64%
+167%+28%-111%
Nov 15, 20215 yearsNov 16, 2026

Percent change in share price from the first common trading day shown; excludes dividends.

Head-to-head

JBIO versus OMER key metrics
MetricJBIOOMER
Share price$15.31$13.21
Market cap$1.06B$983.66M
1-day change+1.66%-5.71%
YTD return-0.78%-23.11%
1-year return+27.58%+48.93%
5-year return-96.69%+77.79%
P/E ratio (TTM)—15.92
Forward P/E—11.95
EPS (TTM)$-1.83$0.83
Dividend yield0.00%0.00%
Annual dividend$0.00$0.00
Net income (latest FY)$-127.41M$-3.35M
52-week high$28.00$21.24
52-week low$11.32$6.70
Distance from 52-week high-45.32%-37.81%
Analyst consensusstrong_buybuy
Avg. price target upside+222.53%+108.18%
Average volume917.21K1.36M
Shares outstanding69.19M74.46M
Employees55175
SectorHealth CareHealth Care
IndustryBiotechnology: Pharmaceutical PreparationsBiotechnology: Pharmaceutical Preparations

Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.

Key differences

  • OMER has outperformed JBIO by 21.3 percentage points over the past year.

About Jade Biosciences

JBIO stock →

Jade Biosciences, Inc. operates as a biotechnology company that develops therapies for inflammation and immunology indications in patients living with autoimmune diseases.

Health Care · Biotechnology: Pharmaceutical Preparations · 55 employees

About Omeros

OMER stock →

Omeros Corporation, a clinical-stage biopharmaceutical company, discovers, develops, and commercializes small-molecule and protein therapeutics, and orphan indications targeting immunologic diseases. The company's lead products candidate is the Narsoplimab (OMS721/MASP-2) for the treatment of hematopoietic stem-cell transplant-associated thrombotic microangiopathy (TA-TMA); and in Phase II clinical trial to treat COVID-19 and acute respiratory distress syndrome.

Health Care · Biotechnology: Pharmaceutical Preparations · 175 employees

JBIO vs OMER FAQ

Which is bigger, Jade Biosciences or Omeros?

Jade Biosciences (JBIO) is larger, with a market capitalization of $1.06B compared with $983.66M for Omeros (OMER).

Which stock has performed better over the past year, JBIO or OMER?

OMER returned +48.93% over the past 12 months, compared with +27.58% for JBIO (price return, excluding dividends). Past performance does not predict future results.

Are Jade Biosciences and Omeros in the same industry?

Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.

More comparisons